Astellas Pharma Inc. Logo

Astellas Pharma Inc.

A global pharmaceutical company developing innovative medicines for unmet needs, focusing on oncology.

4503 | T

Overview

Corporate Details

ISIN(s):
JP3942400007
LEI:
Country:
Japan
Address:
中央区日本橋本町二丁目5番1号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Astellas Pharma Inc. is a global pharmaceutical company dedicated to improving human health by turning innovative science into value for patients. Formed in 2005 from the merger of Yamanouchi Pharmaceutical Co. and Fujisawa Pharmaceutical Co., the company engages in the research, development, manufacturing, and marketing of innovative pharmaceutical products. Astellas focuses on addressing unmet medical needs in several therapeutic areas, with a primary emphasis on oncology. Its key areas of innovation also include gene therapy, immuno-oncology, regenerative medicine, and treatments for blindness and mitochondrial diseases. The company is committed to a stable supply of reliable medicines worldwide and stands at the forefront of healthcare change.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-06 03:29
Report Publication Announcement
確認書
Japanese 8.9 KB
2025-11-06 03:26
Interim Report
半期報告書-第21期(2025/04/01-2026/03/31)
Japanese 310.0 KB
2025-07-31 08:30
Registration Form
訂正発行登録書
Japanese 9.7 KB
2025-07-31 04:04
Post-Annual General Meeting Information
訂正臨時報告書
Japanese 33.0 KB
2025-07-03 08:31
Registration Form
訂正発行登録書
Japanese 10.3 KB
2025-07-02 02:28
Post-Annual General Meeting Information
臨時報告書
Japanese 24.1 KB
2025-06-16 06:14
Governance Information
内部統制報告書-第20期(2024/04/01-2025/03/31)
Japanese 23.1 KB
2025-06-16 06:11
Registration Form
確認書
Japanese 8.7 KB
2025-06-16 06:09
Annual Report
有価証券報告書-第20期(2024/04/01-2025/03/31)
Japanese 2.5 MB
2025-02-04 07:47
Registration Form
訂正発行登録書
Japanese 9.9 KB
2025-02-04 07:40
Regulatory News Service
臨時報告書
Japanese 19.4 KB
2025-02-04 07:39
Regulatory News Service
臨時報告書
Japanese 20.9 KB
2024-11-06 05:52
Interim Report
確認書
Japanese 8.9 KB
2024-11-06 05:51
Interim Report
半期報告書-第20期(2024/04/01-2025/03/31)
Japanese 344.2 KB
2024-09-03 03:34
Registration Form
発行登録追補書類(株券、社債券等)
Japanese 96.0 KB

Automate Your Workflow. Get a real-time feed of all Astellas Pharma Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Astellas Pharma Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Astellas Pharma Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB
MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America
MGNX

Talk to a Data Expert

Have a question? We'll get back to you promptly.